Clinical trials: Immune Deficiencies
Amyloidosis
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .
- Trial name
- ALANIS (NCT07224672)
- Testing
- Belantamab mafodotin, Cyclophosphamide, Bortezomib
- Where
- 5 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
AL Amyloidosis
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04304144
- Testing
- CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS
The objective of this study is to evaluate the safety of intrathecal administration of Wharton's Jelly Mesenchymal Stem Cells (WJMSC) and the impact on the immune system of patients with Amyotrophic Lateral Sclerosis.
- Trial name
- ALSTEM (NCT04651855)
- Testing
- Mesenchymal stem cells isolated from Wharton's jelly
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Polski Bank Komorek Macierzystych JSC (PBKM)
Amyloidosis, AL Amyloidosis
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis.
- Trial name
- NCT05199337
- Testing
- ZN-d5
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 18 people
- Sponsor
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Amyloidosis
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
GSK3039294 has been developed in order to offer an orally available alternative to parenteral CPHPC (GSK2315698 [metabolite of GSK3039294]) for plasma serum amyloid P component (SAP) depletion prior to use of anti SAP monoclonal…
- Trial name
- NCT02603172
- Testing
- GSK3039294
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
AL Amyloidosis, Amyloidosis
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
This is an online registry to document the psychometric properties of SF-36v2 among patients with AL Amyloidosis, to document patients' burden of disease, to better understand the patient's experience and to follow quality of…
- Trial name
- NCT02574676
- Testing
- non-interventional
- Where
- United States
- Volunteers
- 343 people
- Sponsor
- Prothena Biosciences Ltd.
Multiple Myeloma, Lymphoma
Ixazomib Rollover Study
The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
- Conditions
- Multiple Myeloma, Lymphoma, Amyloidosis
- Trial name
- NCT02924272
- Testing
- Ixazomib
- Where
- 26 sites in United States, Belgium and 9 more
- Volunteers
- 32 people
- Sponsor
- Takeda
Amyloidosis; Systemic
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess…
- Trial name
- AT02-001 (NCT05521022)
- Testing
- AT-02
- Where
- 11 sites in United States, Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Attralus, Inc.
AL Amyloidosis
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
The goal of this clinical trial is to learn if Equecabtagene Autoleucel(Eque-cel), a Chimeric Antigen Receptor T-cell (CAR-T) therapy, works to treat severe Light Chain (AL) Amyloidosis in newly diagnosed adults with Mayo Stage…
- Trial name
- NCT07055724
- Testing
- Eque-cel CAR-T Therapy
- Volunteers
- 17 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
AL Amyloidosis
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who…
- Trial name
- PRONTO (NCT02632786)
- Testing
- NEOD001
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Prothena Biosciences Ltd.
Iron-Deficiency Anemia
Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy
Multicentre, randomised, controlled, 2-arm open-label prospective pilot study to evaluate efficacy and safety of ferric carboxymaltose (FCM) in treatment of anaemia in subjects with multiple myeloma (MM) initiating chemotherapy.
- Trial name
- AOC-MM (NCT01100879)
- Testing
- Ferric carboxymaltose
- Where
- 2 sites in France, Greece
- Volunteers
- 3 people
- Sponsor
- Vifor Pharma
AL Amyloidosis
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
This is a phase 1/2 open label study of melphalan flufenamide (melflufen) in combination with dexamethasone for participants with Al amyloidosis following at least one prior line of therapy.
- Trial name
- NCT04115956
- Testing
- Melphalan-Flufenamide (Melflufen), Dexamethasone
- Where
- 9 sites in United States, Czechia and 7 more
- Volunteers
- 6 people
- Sponsor
- Oncopeptides AB
Iron-Deficiency Anemia
Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy
Anaemia and functional iron deficiency are common conditions in patients with lymphoid malignancies, conditions which reduce significantly the quality of life and increase morbidity and mortality.
- Trial name
- FID-CHEMO (NCT01101399)
- Testing
- Ferric carboxymaltose
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 19 people
- Sponsor
- Vifor Pharma
Cuff Tear Arthropathy, Osteoarthritis With Cuff Deficiency
Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder
This post-marketing study is designed to collect data relating to the use of the Delta Xtend™ Total Shoulder Replacement System in shoulder with rotator cuff deficiencies.
- Conditions
- Cuff Tear Arthropathy, Osteoarthritis With Cuff Deficiency, Rheumatoid Arthritis, Post Traumatic Injury to Shoulder
- Trial name
- NCT00737087
- Testing
- Delta Xtend Reverse Total Shoulder
- Where
- 5 sites in Belgium, France and 1 more
- Volunteers
- 144 people
- Sponsor
- DePuy International
Amyloidosis
SAP Depleter Dose Assessment Study in Patients
This study aims to provide safety information on the ligand, GSK2315698A. The pharmacokinetics and pharmacodynamics of the ligand will be determined together with the differences in routes of dose administration, namely the…
- Trial name
- NCT01406314
- Testing
- GSK2315698
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Primary Light Chain (AL) Amyloidosis
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
This Phase I study is designed to evaluate the safety and efficacy of FKC289 in subjects with relapsed/refractory primary light chain (AL) amyloidosis.The primary objectives are to assess the safety of FKC289 and to establish the…
- Trial name
- NCT07765524
- Testing
- FKC289 infusion
- Where
- 11 sites in China
- Volunteers
- 32 people
- Sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Malnutrition; Mild, Iron-deficiency Anemia
The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers
It is well known than an important part of Nigerian children from the lower social economic class have nutrient deficiencies. Fortified products, such as growing up milks (GUM), may play an important role in reducing the risk and…
- Conditions
- Malnutrition; Mild, Iron-deficiency Anemia, Nutritional Stunting, Nutritional Wasting
- Trial name
- GaGA (NCT03411590)
- Testing
- Fortified milk Powder
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- FrieslandCampina WAMCO Nigeria PLC
Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at…
- Trial name
- NCT05652335
- Testing
- JNJ-79635322
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 180 people
- Sponsor
- Janssen Research & Development, LLC
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures